nodes	percent_of_prediction	percent_of_DWPC	metapath
Haloperidol—UGT1A9—Mycophenolic acid—psoriasis	0.105	0.137	CbGbCtD
Haloperidol—CYP1A1—Clobetasol propionate—psoriasis	0.0809	0.105	CbGbCtD
Haloperidol—UGT1A9—Mycophenolate mofetil—psoriasis	0.0588	0.0764	CbGbCtD
Haloperidol—CYP1A1—Methoxsalen—psoriasis	0.0425	0.0553	CbGbCtD
Haloperidol—CYP3A5—Beclomethasone—psoriasis	0.0368	0.0478	CbGbCtD
Haloperidol—CYP1A2—Clobetasol propionate—psoriasis	0.0361	0.047	CbGbCtD
Haloperidol—CYP1A1—Cholecalciferol—psoriasis	0.0282	0.0366	CbGbCtD
Haloperidol—CYP1A2—Methoxsalen—psoriasis	0.019	0.0247	CbGbCtD
Haloperidol—CYP2D6—Hydroxyurea—psoriasis	0.0171	0.0222	CbGbCtD
Haloperidol—CYP3A7—Hydrocortisone—psoriasis	0.0157	0.0204	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.0157	0.0204	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0148	0.0192	CbGbCtD
Haloperidol—CYP3A7—Cyclosporine—psoriasis	0.0148	0.0192	CbGbCtD
Haloperidol—CYP3A5—Mycophenolate mofetil—psoriasis	0.0147	0.019	CbGbCtD
Haloperidol—CYP2C19—Cholecalciferol—psoriasis	0.0136	0.0177	CbGbCtD
Haloperidol—CYP3A4—Calcitriol—psoriasis	0.0128	0.0166	CbGbCtD
Haloperidol—CYP1A1—Dexamethasone—psoriasis	0.0122	0.0158	CbGbCtD
Haloperidol—CYP3A5—Hydrocortisone—psoriasis	0.0118	0.0153	CbGbCtD
Haloperidol—CYP2C9—Cholecalciferol—psoriasis	0.0113	0.0147	CbGbCtD
Haloperidol—CYP3A5—Cyclosporine—psoriasis	0.0111	0.0144	CbGbCtD
Haloperidol—CYP2D6—Cholecalciferol—psoriasis	0.0104	0.0135	CbGbCtD
Haloperidol—CYP3A4—Methoxsalen—psoriasis	0.00995	0.0129	CbGbCtD
Haloperidol—CYP3A7—Dexamethasone—psoriasis	0.00975	0.0127	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.00975	0.0127	CbGbCtD
Haloperidol—ABCB1—Mycophenolate mofetil—psoriasis	0.00954	0.0124	CbGbCtD
Haloperidol—CYP2C19—Prednisone—psoriasis	0.00945	0.0123	CbGbCtD
Haloperidol—CYP2C19—Cyclosporine—psoriasis	0.00896	0.0116	CbGbCtD
Haloperidol—ABCB1—Betamethasone—psoriasis	0.00818	0.0106	CbGbCtD
Haloperidol—ABCB1—Prednisolone—psoriasis	0.00807	0.0105	CbGbCtD
Haloperidol—ABCB1—Hydrocortisone—psoriasis	0.00765	0.00995	CbGbCtD
Haloperidol—ABCB1—Prednisone—psoriasis	0.00762	0.00991	CbGbCtD
Haloperidol—CYP2C9—Cyclosporine—psoriasis	0.00745	0.00968	CbGbCtD
Haloperidol—CYP3A5—Dexamethasone—psoriasis	0.00731	0.00951	CbGbCtD
Haloperidol—ABCB1—Cyclosporine—psoriasis	0.00723	0.00939	CbGbCtD
Haloperidol—CYP2D6—Cyclosporine—psoriasis	0.00681	0.00885	CbGbCtD
Haloperidol—CYP3A4—Cholecalciferol—psoriasis	0.00659	0.00857	CbGbCtD
Haloperidol—CYP2C19—Dexamethasone—psoriasis	0.0059	0.00767	CbGbCtD
Haloperidol—CYP3A4—Triamcinolone—psoriasis	0.00571	0.00743	CbGbCtD
Haloperidol—CYP3A4—Mycophenolate mofetil—psoriasis	0.00571	0.00743	CbGbCtD
Haloperidol—CYP2C9—Dexamethasone—psoriasis	0.0049	0.00638	CbGbCtD
Haloperidol—CYP3A4—Betamethasone—psoriasis	0.0049	0.00637	CbGbCtD
Haloperidol—CYP3A4—Prednisolone—psoriasis	0.00484	0.00629	CbGbCtD
Haloperidol—ABCB1—Dexamethasone—psoriasis	0.00476	0.00619	CbGbCtD
Haloperidol—CYP3A4—Hydrocortisone—psoriasis	0.00458	0.00596	CbGbCtD
Haloperidol—CYP3A4—Prednisone—psoriasis	0.00457	0.00594	CbGbCtD
Haloperidol—CYP2D6—Dexamethasone—psoriasis	0.00448	0.00583	CbGbCtD
Haloperidol—CYP3A4—Cyclosporine—psoriasis	0.00433	0.00563	CbGbCtD
Haloperidol—ABCB1—Methotrexate—psoriasis	0.00382	0.00497	CbGbCtD
Haloperidol—CYP3A4—Dexamethasone—psoriasis	0.00285	0.00371	CbGbCtD
Haloperidol—SIGMAR1—Levonorgestrel—Hydrocortisone—psoriasis	0.000678	1	CbGdCrCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.000138	0.00076	CcSEcCtD
Haloperidol—Connective tissue disorder—Prednisone—psoriasis	0.000137	0.000755	CcSEcCtD
Haloperidol—Hypotension—Mycophenolate mofetil—psoriasis	0.000137	0.000752	CcSEcCtD
Haloperidol—Oedema—Prednisolone—psoriasis	0.000136	0.000751	CcSEcCtD
Haloperidol—Anaphylactic shock—Prednisolone—psoriasis	0.000136	0.000751	CcSEcCtD
Haloperidol—Neutropenia—Methotrexate—psoriasis	0.000136	0.00075	CcSEcCtD
Haloperidol—Insomnia—Cyclosporine—psoriasis	0.000136	0.000746	CcSEcCtD
Haloperidol—Erectile dysfunction—Methotrexate—psoriasis	0.000134	0.000739	CcSEcCtD
Haloperidol—Dyspnoea—Cyclosporine—psoriasis	0.000134	0.000736	CcSEcCtD
Haloperidol—Somnolence—Cyclosporine—psoriasis	0.000133	0.000734	CcSEcCtD
Haloperidol—Oedema—Hydrocortisone—psoriasis	0.000133	0.000733	CcSEcCtD
Haloperidol—Anaphylactic shock—Hydrocortisone—psoriasis	0.000133	0.000733	CcSEcCtD
Haloperidol—Convulsion—Triamcinolone—psoriasis	0.000133	0.000733	CcSEcCtD
Haloperidol—Tachycardia—Prednisolone—psoriasis	0.000133	0.000733	CcSEcCtD
Haloperidol—Photosensitivity reaction—Methotrexate—psoriasis	0.000133	0.000732	CcSEcCtD
Haloperidol—Hypertension—Triamcinolone—psoriasis	0.000133	0.00073	CcSEcCtD
Haloperidol—Insomnia—Mycophenolate mofetil—psoriasis	0.000132	0.000728	CcSEcCtD
Haloperidol—Dyspepsia—Cyclosporine—psoriasis	0.000132	0.000726	CcSEcCtD
Haloperidol—Hyperhidrosis—Prednisolone—psoriasis	0.000132	0.000726	CcSEcCtD
Haloperidol—Nausea—Hydroxyurea—psoriasis	0.000131	0.000723	CcSEcCtD
Haloperidol—Pruritus—Mycophenolic acid—psoriasis	0.000131	0.000722	CcSEcCtD
Haloperidol—Nervous system disorder—Hydrocortisone—psoriasis	0.000131	0.000719	CcSEcCtD
Haloperidol—Eye disorder—Prednisone—psoriasis	0.00013	0.000718	CcSEcCtD
Haloperidol—Dyspnoea—Mycophenolate mofetil—psoriasis	0.00013	0.000718	CcSEcCtD
Haloperidol—Decreased appetite—Cyclosporine—psoriasis	0.00013	0.000717	CcSEcCtD
Haloperidol—Tachycardia—Hydrocortisone—psoriasis	0.00013	0.000716	CcSEcCtD
Haloperidol—Somnolence—Mycophenolate mofetil—psoriasis	0.00013	0.000716	CcSEcCtD
Haloperidol—Drowsiness—Methotrexate—psoriasis	0.00013	0.000715	CcSEcCtD
Haloperidol—Depression—Methotrexate—psoriasis	0.00013	0.000713	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000129	0.000712	CcSEcCtD
Haloperidol—Skin disorder—Hydrocortisone—psoriasis	0.000129	0.000712	CcSEcCtD
Haloperidol—Hyperhidrosis—Hydrocortisone—psoriasis	0.000129	0.000709	CcSEcCtD
Haloperidol—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000129	0.000709	CcSEcCtD
Haloperidol—Constipation—Cyclosporine—psoriasis	0.000128	0.000706	CcSEcCtD
Haloperidol—Dry mouth—Triamcinolone—psoriasis	0.000128	0.000704	CcSEcCtD
Haloperidol—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000127	0.0007	CcSEcCtD
Haloperidol—Anorexia—Hydrocortisone—psoriasis	0.000127	0.000699	CcSEcCtD
Haloperidol—Diarrhoea—Mycophenolic acid—psoriasis	0.000127	0.000698	CcSEcCtD
Haloperidol—Angiopathy—Prednisone—psoriasis	0.000127	0.000697	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000126	0.000695	CcSEcCtD
Haloperidol—Immune system disorder—Prednisone—psoriasis	0.000126	0.000694	CcSEcCtD
Haloperidol—Anaphylactic shock—Triamcinolone—psoriasis	0.000125	0.000691	CcSEcCtD
Haloperidol—Oedema—Triamcinolone—psoriasis	0.000125	0.000691	CcSEcCtD
Haloperidol—Vertigo—Dexamethasone—psoriasis	0.000125	0.00069	CcSEcCtD
Haloperidol—Vertigo—Betamethasone—psoriasis	0.000125	0.00069	CcSEcCtD
Haloperidol—Constipation—Mycophenolate mofetil—psoriasis	0.000125	0.000688	CcSEcCtD
Haloperidol—Hypotension—Hydrocortisone—psoriasis	0.000124	0.000685	CcSEcCtD
Haloperidol—Feeling abnormal—Cyclosporine—psoriasis	0.000124	0.00068	CcSEcCtD
Haloperidol—Insomnia—Prednisolone—psoriasis	0.000123	0.000679	CcSEcCtD
Haloperidol—Alopecia—Prednisone—psoriasis	0.000123	0.000679	CcSEcCtD
Haloperidol—Hepatobiliary disease—Methotrexate—psoriasis	0.000123	0.000676	CcSEcCtD
Haloperidol—Dizziness—Mycophenolic acid—psoriasis	0.000123	0.000675	CcSEcCtD
Haloperidol—Tachycardia—Triamcinolone—psoriasis	0.000122	0.000674	CcSEcCtD
Haloperidol—Mental disorder—Prednisone—psoriasis	0.000122	0.000673	CcSEcCtD
Haloperidol—Malnutrition—Prednisone—psoriasis	0.000121	0.000669	CcSEcCtD
Haloperidol—Hyperhidrosis—Triamcinolone—psoriasis	0.000121	0.000668	CcSEcCtD
Haloperidol—Agranulocytosis—Methotrexate—psoriasis	0.000121	0.000667	CcSEcCtD
Haloperidol—Convulsion—Dexamethasone—psoriasis	0.000121	0.000665	CcSEcCtD
Haloperidol—Convulsion—Betamethasone—psoriasis	0.000121	0.000665	CcSEcCtD
Haloperidol—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000121	0.000663	CcSEcCtD
Haloperidol—Insomnia—Hydrocortisone—psoriasis	0.000121	0.000663	CcSEcCtD
Haloperidol—Hypertension—Dexamethasone—psoriasis	0.00012	0.000663	CcSEcCtD
Haloperidol—Hypertension—Betamethasone—psoriasis	0.00012	0.000663	CcSEcCtD
Haloperidol—Urticaria—Cyclosporine—psoriasis	0.000119	0.000656	CcSEcCtD
Haloperidol—Body temperature increased—Cyclosporine—psoriasis	0.000119	0.000652	CcSEcCtD
Haloperidol—Anxiety—Betamethasone—psoriasis	0.000118	0.000651	CcSEcCtD
Haloperidol—Anxiety—Dexamethasone—psoriasis	0.000118	0.000651	CcSEcCtD
Haloperidol—Vomiting—Mycophenolic acid—psoriasis	0.000118	0.000649	CcSEcCtD
Haloperidol—Dyspepsia—Hydrocortisone—psoriasis	0.000117	0.000646	CcSEcCtD
Haloperidol—Rash—Mycophenolic acid—psoriasis	0.000117	0.000643	CcSEcCtD
Haloperidol—Dermatitis—Mycophenolic acid—psoriasis	0.000117	0.000643	CcSEcCtD
Haloperidol—Hepatitis—Methotrexate—psoriasis	0.000117	0.000642	CcSEcCtD
Haloperidol—Urticaria—Mycophenolate mofetil—psoriasis	0.000116	0.000639	CcSEcCtD
Haloperidol—Headache—Mycophenolic acid—psoriasis	0.000116	0.000639	CcSEcCtD
Haloperidol—Decreased appetite—Hydrocortisone—psoriasis	0.000116	0.000637	CcSEcCtD
Haloperidol—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000116	0.000636	CcSEcCtD
Haloperidol—Urinary tract disorder—Methotrexate—psoriasis	0.000115	0.000634	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000115	0.000633	CcSEcCtD
Haloperidol—Vision blurred—Prednisone—psoriasis	0.000114	0.00063	CcSEcCtD
Haloperidol—Urethral disorder—Methotrexate—psoriasis	0.000114	0.000629	CcSEcCtD
Haloperidol—Anaphylactic shock—Betamethasone—psoriasis	0.000114	0.000627	CcSEcCtD
Haloperidol—Oedema—Betamethasone—psoriasis	0.000114	0.000627	CcSEcCtD
Haloperidol—Anaphylactic shock—Dexamethasone—psoriasis	0.000114	0.000627	CcSEcCtD
Haloperidol—Oedema—Dexamethasone—psoriasis	0.000114	0.000627	CcSEcCtD
Haloperidol—Insomnia—Triamcinolone—psoriasis	0.000113	0.000625	CcSEcCtD
Haloperidol—Feeling abnormal—Prednisolone—psoriasis	0.000112	0.000619	CcSEcCtD
Haloperidol—Visual impairment—Methotrexate—psoriasis	0.000112	0.000619	CcSEcCtD
Haloperidol—Anaemia—Prednisone—psoriasis	0.000112	0.000618	CcSEcCtD
Haloperidol—Dyspnoea—Triamcinolone—psoriasis	0.000112	0.000616	CcSEcCtD
Haloperidol—Nervous system disorder—Dexamethasone—psoriasis	0.000112	0.000614	CcSEcCtD
Haloperidol—Nervous system disorder—Betamethasone—psoriasis	0.000112	0.000614	CcSEcCtD
Haloperidol—Agitation—Prednisone—psoriasis	0.000112	0.000614	CcSEcCtD
Haloperidol—Thrombocytopenia—Betamethasone—psoriasis	0.000111	0.000613	CcSEcCtD
Haloperidol—Thrombocytopenia—Dexamethasone—psoriasis	0.000111	0.000613	CcSEcCtD
Haloperidol—Tachycardia—Betamethasone—psoriasis	0.000111	0.000611	CcSEcCtD
Haloperidol—Tachycardia—Dexamethasone—psoriasis	0.000111	0.000611	CcSEcCtD
Haloperidol—Hypersensitivity—Cyclosporine—psoriasis	0.00011	0.000608	CcSEcCtD
Haloperidol—Dyspepsia—Triamcinolone—psoriasis	0.00011	0.000608	CcSEcCtD
Haloperidol—Nausea—Mycophenolic acid—psoriasis	0.00011	0.000606	CcSEcCtD
Haloperidol—Hyperhidrosis—Betamethasone—psoriasis	0.00011	0.000606	CcSEcCtD
Haloperidol—Hyperhidrosis—Dexamethasone—psoriasis	0.00011	0.000606	CcSEcCtD
Haloperidol—Feeling abnormal—Hydrocortisone—psoriasis	0.00011	0.000604	CcSEcCtD
Haloperidol—Vertigo—Prednisone—psoriasis	0.000109	0.000601	CcSEcCtD
Haloperidol—Eye disorder—Methotrexate—psoriasis	0.000109	0.0006	CcSEcCtD
Haloperidol—Anorexia—Dexamethasone—psoriasis	0.000109	0.000597	CcSEcCtD
Haloperidol—Anorexia—Betamethasone—psoriasis	0.000109	0.000597	CcSEcCtD
Haloperidol—Urticaria—Prednisolone—psoriasis	0.000108	0.000597	CcSEcCtD
Haloperidol—Cardiac disorder—Methotrexate—psoriasis	0.000108	0.000596	CcSEcCtD
Haloperidol—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000108	0.000593	CcSEcCtD
Haloperidol—Hypotension—Dexamethasone—psoriasis	0.000106	0.000585	CcSEcCtD
Haloperidol—Hypotension—Betamethasone—psoriasis	0.000106	0.000585	CcSEcCtD
Haloperidol—Pruritus—Cyclosporine—psoriasis	0.000106	0.000584	CcSEcCtD
Haloperidol—Urticaria—Hydrocortisone—psoriasis	0.000106	0.000583	CcSEcCtD
Haloperidol—Angiopathy—Methotrexate—psoriasis	0.000106	0.000582	CcSEcCtD
Haloperidol—Immune system disorder—Methotrexate—psoriasis	0.000105	0.00058	CcSEcCtD
Haloperidol—Body temperature increased—Hydrocortisone—psoriasis	0.000105	0.00058	CcSEcCtD
Haloperidol—Convulsion—Prednisone—psoriasis	0.000105	0.000579	CcSEcCtD
Haloperidol—Mediastinal disorder—Methotrexate—psoriasis	0.000105	0.000578	CcSEcCtD
Haloperidol—Hypertension—Prednisone—psoriasis	0.000105	0.000577	CcSEcCtD
Haloperidol—Pruritus—Mycophenolate mofetil—psoriasis	0.000103	0.00057	CcSEcCtD
Haloperidol—Feeling abnormal—Triamcinolone—psoriasis	0.000103	0.000569	CcSEcCtD
Haloperidol—Anxiety—Prednisone—psoriasis	0.000103	0.000567	CcSEcCtD
Haloperidol—Alopecia—Methotrexate—psoriasis	0.000103	0.000567	CcSEcCtD
Haloperidol—Insomnia—Betamethasone—psoriasis	0.000103	0.000567	CcSEcCtD
Haloperidol—Insomnia—Dexamethasone—psoriasis	0.000103	0.000567	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000103	0.000565	CcSEcCtD
Haloperidol—Diarrhoea—Cyclosporine—psoriasis	0.000103	0.000565	CcSEcCtD
Haloperidol—Mental disorder—Methotrexate—psoriasis	0.000102	0.000562	CcSEcCtD
Haloperidol—Malnutrition—Methotrexate—psoriasis	0.000102	0.000559	CcSEcCtD
Haloperidol—Hypersensitivity—Prednisolone—psoriasis	0.000101	0.000553	CcSEcCtD
Haloperidol—Dyspepsia—Betamethasone—psoriasis	0.0001	0.000552	CcSEcCtD
Haloperidol—Dyspepsia—Dexamethasone—psoriasis	0.0001	0.000552	CcSEcCtD
Haloperidol—Diarrhoea—Mycophenolate mofetil—psoriasis	0.0001	0.000551	CcSEcCtD
Haloperidol—Urticaria—Triamcinolone—psoriasis	9.97e-05	0.000549	CcSEcCtD
Haloperidol—Body temperature increased—Triamcinolone—psoriasis	9.92e-05	0.000546	CcSEcCtD
Haloperidol—Dizziness—Cyclosporine—psoriasis	9.91e-05	0.000546	CcSEcCtD
Haloperidol—Anaphylactic shock—Prednisone—psoriasis	9.91e-05	0.000546	CcSEcCtD
Haloperidol—Oedema—Prednisone—psoriasis	9.91e-05	0.000546	CcSEcCtD
Haloperidol—Decreased appetite—Betamethasone—psoriasis	9.89e-05	0.000545	CcSEcCtD
Haloperidol—Decreased appetite—Dexamethasone—psoriasis	9.89e-05	0.000545	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Dexamethasone—psoriasis	9.83e-05	0.000541	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Betamethasone—psoriasis	9.83e-05	0.000541	CcSEcCtD
Haloperidol—Hypersensitivity—Hydrocortisone—psoriasis	9.82e-05	0.00054	CcSEcCtD
Haloperidol—Nervous system disorder—Prednisone—psoriasis	9.72e-05	0.000535	CcSEcCtD
Haloperidol—Tachycardia—Prednisone—psoriasis	9.67e-05	0.000533	CcSEcCtD
Haloperidol—Dizziness—Mycophenolate mofetil—psoriasis	9.67e-05	0.000532	CcSEcCtD
Haloperidol—Skin disorder—Prednisone—psoriasis	9.63e-05	0.00053	CcSEcCtD
Haloperidol—Hyperhidrosis—Prednisone—psoriasis	9.58e-05	0.000527	CcSEcCtD
Haloperidol—Vision blurred—Methotrexate—psoriasis	9.57e-05	0.000527	CcSEcCtD
Haloperidol—Vomiting—Cyclosporine—psoriasis	9.53e-05	0.000525	CcSEcCtD
Haloperidol—Rash—Cyclosporine—psoriasis	9.45e-05	0.00052	CcSEcCtD
Haloperidol—Anorexia—Prednisone—psoriasis	9.45e-05	0.00052	CcSEcCtD
Haloperidol—Dermatitis—Cyclosporine—psoriasis	9.44e-05	0.00052	CcSEcCtD
Haloperidol—Pruritus—Hydrocortisone—psoriasis	9.43e-05	0.000519	CcSEcCtD
Haloperidol—Headache—Cyclosporine—psoriasis	9.39e-05	0.000517	CcSEcCtD
Haloperidol—Anaemia—Methotrexate—psoriasis	9.38e-05	0.000516	CcSEcCtD
Haloperidol—Feeling abnormal—Dexamethasone—psoriasis	9.38e-05	0.000516	CcSEcCtD
Haloperidol—Feeling abnormal—Betamethasone—psoriasis	9.38e-05	0.000516	CcSEcCtD
Haloperidol—Vomiting—Mycophenolate mofetil—psoriasis	9.3e-05	0.000512	CcSEcCtD
Haloperidol—Hypersensitivity—Triamcinolone—psoriasis	9.24e-05	0.000509	CcSEcCtD
Haloperidol—Rash—Mycophenolate mofetil—psoriasis	9.22e-05	0.000508	CcSEcCtD
Haloperidol—Dermatitis—Mycophenolate mofetil—psoriasis	9.21e-05	0.000507	CcSEcCtD
Haloperidol—Headache—Mycophenolate mofetil—psoriasis	9.16e-05	0.000504	CcSEcCtD
Haloperidol—Vertigo—Methotrexate—psoriasis	9.12e-05	0.000502	CcSEcCtD
Haloperidol—Diarrhoea—Hydrocortisone—psoriasis	9.12e-05	0.000502	CcSEcCtD
Haloperidol—Leukopenia—Methotrexate—psoriasis	9.09e-05	0.0005	CcSEcCtD
Haloperidol—Urticaria—Betamethasone—psoriasis	9.04e-05	0.000498	CcSEcCtD
Haloperidol—Urticaria—Dexamethasone—psoriasis	9.04e-05	0.000498	CcSEcCtD
Haloperidol—Dizziness—Prednisolone—psoriasis	9.02e-05	0.000497	CcSEcCtD
Haloperidol—Body temperature increased—Betamethasone—psoriasis	9e-05	0.000495	CcSEcCtD
Haloperidol—Body temperature increased—Dexamethasone—psoriasis	9e-05	0.000495	CcSEcCtD
Haloperidol—Insomnia—Prednisone—psoriasis	8.97e-05	0.000494	CcSEcCtD
Haloperidol—Nausea—Cyclosporine—psoriasis	8.9e-05	0.00049	CcSEcCtD
Haloperidol—Pruritus—Triamcinolone—psoriasis	8.88e-05	0.000489	CcSEcCtD
Haloperidol—Dizziness—Hydrocortisone—psoriasis	8.81e-05	0.000485	CcSEcCtD
Haloperidol—Convulsion—Methotrexate—psoriasis	8.79e-05	0.000484	CcSEcCtD
Haloperidol—Dyspepsia—Prednisone—psoriasis	8.73e-05	0.00048	CcSEcCtD
Haloperidol—Nausea—Mycophenolate mofetil—psoriasis	8.69e-05	0.000478	CcSEcCtD
Haloperidol—Decreased appetite—Prednisone—psoriasis	8.62e-05	0.000474	CcSEcCtD
Haloperidol—Rash—Prednisolone—psoriasis	8.6e-05	0.000473	CcSEcCtD
Haloperidol—Dermatitis—Prednisolone—psoriasis	8.59e-05	0.000473	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	8.58e-05	0.000472	CcSEcCtD
Haloperidol—Headache—Prednisolone—psoriasis	8.55e-05	0.00047	CcSEcCtD
Haloperidol—Constipation—Prednisone—psoriasis	8.48e-05	0.000467	CcSEcCtD
Haloperidol—Vomiting—Hydrocortisone—psoriasis	8.47e-05	0.000466	CcSEcCtD
Haloperidol—Rash—Hydrocortisone—psoriasis	8.4e-05	0.000462	CcSEcCtD
Haloperidol—Dermatitis—Hydrocortisone—psoriasis	8.39e-05	0.000462	CcSEcCtD
Haloperidol—Confusional state—Methotrexate—psoriasis	8.35e-05	0.00046	CcSEcCtD
Haloperidol—Headache—Hydrocortisone—psoriasis	8.35e-05	0.000459	CcSEcCtD
Haloperidol—Dizziness—Triamcinolone—psoriasis	8.3e-05	0.000457	CcSEcCtD
Haloperidol—Anaphylactic shock—Methotrexate—psoriasis	8.28e-05	0.000456	CcSEcCtD
Haloperidol—Feeling abnormal—Prednisone—psoriasis	8.17e-05	0.00045	CcSEcCtD
Haloperidol—Nervous system disorder—Methotrexate—psoriasis	8.12e-05	0.000447	CcSEcCtD
Haloperidol—Thrombocytopenia—Methotrexate—psoriasis	8.11e-05	0.000446	CcSEcCtD
Haloperidol—Nausea—Prednisolone—psoriasis	8.1e-05	0.000446	CcSEcCtD
Haloperidol—Pruritus—Dexamethasone—psoriasis	8.05e-05	0.000443	CcSEcCtD
Haloperidol—Pruritus—Betamethasone—psoriasis	8.05e-05	0.000443	CcSEcCtD
Haloperidol—Skin disorder—Methotrexate—psoriasis	8.05e-05	0.000443	CcSEcCtD
Haloperidol—Hyperhidrosis—Methotrexate—psoriasis	8.01e-05	0.000441	CcSEcCtD
Haloperidol—Vomiting—Triamcinolone—psoriasis	7.98e-05	0.000439	CcSEcCtD
Haloperidol—Nausea—Hydrocortisone—psoriasis	7.91e-05	0.000436	CcSEcCtD
Haloperidol—Rash—Triamcinolone—psoriasis	7.91e-05	0.000435	CcSEcCtD
Haloperidol—Dermatitis—Triamcinolone—psoriasis	7.9e-05	0.000435	CcSEcCtD
Haloperidol—Anorexia—Methotrexate—psoriasis	7.9e-05	0.000435	CcSEcCtD
Haloperidol—Urticaria—Prednisone—psoriasis	7.87e-05	0.000433	CcSEcCtD
Haloperidol—Headache—Triamcinolone—psoriasis	7.86e-05	0.000433	CcSEcCtD
Haloperidol—Body temperature increased—Prednisone—psoriasis	7.84e-05	0.000431	CcSEcCtD
Haloperidol—Diarrhoea—Dexamethasone—psoriasis	7.79e-05	0.000429	CcSEcCtD
Haloperidol—Diarrhoea—Betamethasone—psoriasis	7.79e-05	0.000429	CcSEcCtD
Haloperidol—Hypotension—Methotrexate—psoriasis	7.74e-05	0.000426	CcSEcCtD
Haloperidol—Dizziness—Betamethasone—psoriasis	7.53e-05	0.000414	CcSEcCtD
Haloperidol—Dizziness—Dexamethasone—psoriasis	7.53e-05	0.000414	CcSEcCtD
Haloperidol—Insomnia—Methotrexate—psoriasis	7.49e-05	0.000412	CcSEcCtD
Haloperidol—Nausea—Triamcinolone—psoriasis	7.45e-05	0.00041	CcSEcCtD
Haloperidol—Dyspnoea—Methotrexate—psoriasis	7.39e-05	0.000407	CcSEcCtD
Haloperidol—Somnolence—Methotrexate—psoriasis	7.36e-05	0.000405	CcSEcCtD
Haloperidol—Hypersensitivity—Prednisone—psoriasis	7.3e-05	0.000402	CcSEcCtD
Haloperidol—Dyspepsia—Methotrexate—psoriasis	7.29e-05	0.000401	CcSEcCtD
Haloperidol—Vomiting—Dexamethasone—psoriasis	7.24e-05	0.000398	CcSEcCtD
Haloperidol—Vomiting—Betamethasone—psoriasis	7.24e-05	0.000398	CcSEcCtD
Haloperidol—Decreased appetite—Methotrexate—psoriasis	7.2e-05	0.000396	CcSEcCtD
Haloperidol—Rash—Betamethasone—psoriasis	7.18e-05	0.000395	CcSEcCtD
Haloperidol—Rash—Dexamethasone—psoriasis	7.18e-05	0.000395	CcSEcCtD
Haloperidol—Dermatitis—Dexamethasone—psoriasis	7.17e-05	0.000395	CcSEcCtD
Haloperidol—Dermatitis—Betamethasone—psoriasis	7.17e-05	0.000395	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Methotrexate—psoriasis	7.15e-05	0.000394	CcSEcCtD
Haloperidol—Headache—Dexamethasone—psoriasis	7.13e-05	0.000393	CcSEcCtD
Haloperidol—Headache—Betamethasone—psoriasis	7.13e-05	0.000393	CcSEcCtD
Haloperidol—Pruritus—Prednisone—psoriasis	7.01e-05	0.000386	CcSEcCtD
Haloperidol—Feeling abnormal—Methotrexate—psoriasis	6.83e-05	0.000376	CcSEcCtD
Haloperidol—Diarrhoea—Prednisone—psoriasis	6.78e-05	0.000373	CcSEcCtD
Haloperidol—Nausea—Dexamethasone—psoriasis	6.76e-05	0.000372	CcSEcCtD
Haloperidol—Nausea—Betamethasone—psoriasis	6.76e-05	0.000372	CcSEcCtD
Haloperidol—Urticaria—Methotrexate—psoriasis	6.58e-05	0.000362	CcSEcCtD
Haloperidol—Dizziness—Prednisone—psoriasis	6.56e-05	0.000361	CcSEcCtD
Haloperidol—Body temperature increased—Methotrexate—psoriasis	6.55e-05	0.00036	CcSEcCtD
Haloperidol—Vomiting—Prednisone—psoriasis	6.3e-05	0.000347	CcSEcCtD
Haloperidol—Rash—Prednisone—psoriasis	6.25e-05	0.000344	CcSEcCtD
Haloperidol—Dermatitis—Prednisone—psoriasis	6.24e-05	0.000344	CcSEcCtD
Haloperidol—Headache—Prednisone—psoriasis	6.21e-05	0.000342	CcSEcCtD
Haloperidol—Hypersensitivity—Methotrexate—psoriasis	6.1e-05	0.000336	CcSEcCtD
Haloperidol—Nausea—Prednisone—psoriasis	5.89e-05	0.000324	CcSEcCtD
Haloperidol—Pruritus—Methotrexate—psoriasis	5.86e-05	0.000323	CcSEcCtD
Haloperidol—Diarrhoea—Methotrexate—psoriasis	5.67e-05	0.000312	CcSEcCtD
Haloperidol—Dizziness—Methotrexate—psoriasis	5.48e-05	0.000302	CcSEcCtD
Haloperidol—Vomiting—Methotrexate—psoriasis	5.27e-05	0.00029	CcSEcCtD
Haloperidol—Rash—Methotrexate—psoriasis	5.22e-05	0.000288	CcSEcCtD
Haloperidol—Dermatitis—Methotrexate—psoriasis	5.22e-05	0.000287	CcSEcCtD
Haloperidol—Headache—Methotrexate—psoriasis	5.19e-05	0.000286	CcSEcCtD
Haloperidol—Nausea—Methotrexate—psoriasis	4.92e-05	0.000271	CcSEcCtD
Haloperidol—DRD4—Signaling Pathways—CCL20—psoriasis	2.45e-05	0.000505	CbGpPWpGaD
Haloperidol—DRD2—G alpha (i) signalling events—CXCL8—psoriasis	2.45e-05	0.000505	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.41e-05	0.000497	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—NDUFA5—psoriasis	2.37e-05	0.00049	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—NDUFA5—psoriasis	2.35e-05	0.000486	CbGpPWpGaD
Haloperidol—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	2.34e-05	0.000483	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—CCL20—psoriasis	2.33e-05	0.000482	CbGpPWpGaD
Haloperidol—GRIN2B—Developmental Biology—VEGFA—psoriasis	2.33e-05	0.000481	CbGpPWpGaD
Haloperidol—HTR2A—SIDS Susceptibility Pathways—TNF—psoriasis	2.32e-05	0.00048	CbGpPWpGaD
Haloperidol—GRIN2B—Developmental Biology—STAT3—psoriasis	2.31e-05	0.000476	CbGpPWpGaD
Haloperidol—DRD4—Circadian rythm related genes—IL6—psoriasis	2.29e-05	0.000473	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—CARM1—psoriasis	2.28e-05	0.000471	CbGpPWpGaD
Haloperidol—HTR1D—GPCR ligand binding—CXCL8—psoriasis	2.26e-05	0.000467	CbGpPWpGaD
Haloperidol—GRIN2B—Axon guidance—IL6—psoriasis	2.26e-05	0.000466	CbGpPWpGaD
Haloperidol—DRD1—Circadian rythm related genes—TP53—psoriasis	2.25e-05	0.000465	CbGpPWpGaD
Haloperidol—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	2.23e-05	0.000461	CbGpPWpGaD
Haloperidol—DRD3—Circadian rythm related genes—TP53—psoriasis	2.22e-05	0.000459	CbGpPWpGaD
Haloperidol—HTR1B—GPCR ligand binding—CXCL8—psoriasis	2.21e-05	0.000457	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CCL20—psoriasis	2.2e-05	0.000454	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—CYP2S1—psoriasis	2.19e-05	0.000453	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.19e-05	0.000453	CbGpPWpGaD
Haloperidol—DRD4—GPCR ligand binding—CXCL8—psoriasis	2.18e-05	0.00045	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CCL20—psoriasis	2.17e-05	0.000448	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—CYP2S1—psoriasis	2.14e-05	0.000442	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.13e-05	0.00044	CbGpPWpGaD
Haloperidol—HTR2B—GPCR ligand binding—CXCL8—psoriasis	2.08e-05	0.000429	CbGpPWpGaD
Haloperidol—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	2.07e-05	0.000428	CbGpPWpGaD
Haloperidol—DRD1—Circadian rythm related genes—IL6—psoriasis	2.06e-05	0.000426	CbGpPWpGaD
Haloperidol—DRD3—Circadian rythm related genes—IL6—psoriasis	2.03e-05	0.00042	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—CYP2S1—psoriasis	2.02e-05	0.000417	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—NDUFA5—psoriasis	2.01e-05	0.000415	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—CYP2S1—psoriasis	2e-05	0.000413	CbGpPWpGaD
Haloperidol—GRIN2B—Developmental Biology—TNF—psoriasis	2e-05	0.000412	CbGpPWpGaD
Haloperidol—DRD1—GPCR ligand binding—CXCL8—psoriasis	1.96e-05	0.000405	CbGpPWpGaD
Haloperidol—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.94e-05	0.000401	CbGpPWpGaD
Haloperidol—DRD3—GPCR ligand binding—CXCL8—psoriasis	1.93e-05	0.000399	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—CARM1—psoriasis	1.92e-05	0.000396	CbGpPWpGaD
Haloperidol—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.91e-05	0.000395	CbGpPWpGaD
Haloperidol—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.91e-05	0.000394	CbGpPWpGaD
Haloperidol—HTR2A—SIDS Susceptibility Pathways—IL6—psoriasis	1.88e-05	0.000387	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.88e-05	0.000387	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CYP2S1—psoriasis	1.71e-05	0.000353	CbGpPWpGaD
Haloperidol—DRD2—Circadian rythm related genes—TP53—psoriasis	1.7e-05	0.000351	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CCL20—psoriasis	1.66e-05	0.000343	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.66e-05	0.000343	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CCL20—psoriasis	1.64e-05	0.000338	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CCL20—psoriasis	1.63e-05	0.000337	CbGpPWpGaD
Haloperidol—GRIN2B—Developmental Biology—IL6—psoriasis	1.61e-05	0.000333	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.6e-05	0.00033	CbGpPWpGaD
Haloperidol—DRD2—Circadian rythm related genes—IL6—psoriasis	1.56e-05	0.000321	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—NDUFA5—psoriasis	1.55e-05	0.00032	CbGpPWpGaD
Haloperidol—DRD2—GPCR ligand binding—CXCL8—psoriasis	1.48e-05	0.000306	CbGpPWpGaD
Haloperidol—HTR2A—GPCR ligand binding—CXCL8—psoriasis	1.46e-05	0.000301	CbGpPWpGaD
Haloperidol—HRH1—GPCR ligand binding—CXCL8—psoriasis	1.45e-05	0.0003	CbGpPWpGaD
Haloperidol—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.45e-05	0.0003	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.45e-05	0.0003	CbGpPWpGaD
Haloperidol—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.45e-05	0.000299	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.41e-05	0.00029	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—CAT—psoriasis	1.4e-05	0.00029	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—SOCS1—psoriasis	1.4e-05	0.000289	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—CARM1—psoriasis	1.39e-05	0.000286	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—SOCS1—psoriasis	1.37e-05	0.000283	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—SOCS1—psoriasis	1.35e-05	0.000278	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—TYK2—psoriasis	1.33e-05	0.000275	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CYP2S1—psoriasis	1.32e-05	0.000272	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—CARM1—psoriasis	1.31e-05	0.00027	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—TYK2—psoriasis	1.3e-05	0.000269	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—SOCS1—psoriasis	1.29e-05	0.000265	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—TYK2—psoriasis	1.28e-05	0.000265	CbGpPWpGaD
Haloperidol—HTR1D—GPCR downstream signaling—CXCL8—psoriasis	1.28e-05	0.000264	CbGpPWpGaD
Haloperidol—HTR1B—GPCR downstream signaling—CXCL8—psoriasis	1.25e-05	0.000258	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.24e-05	0.000257	CbGpPWpGaD
Haloperidol—DRD4—GPCR downstream signaling—CXCL8—psoriasis	1.23e-05	0.000254	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—TYK2—psoriasis	1.23e-05	0.000253	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.22e-05	0.000253	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—SOCS1—psoriasis	1.21e-05	0.00025	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—SOCS1—psoriasis	1.2e-05	0.000247	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—CAT—psoriasis	1.18e-05	0.000244	CbGpPWpGaD
Haloperidol—HTR2B—GPCR downstream signaling—CXCL8—psoriasis	1.18e-05	0.000243	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—CXCL8—psoriasis	1.16e-05	0.00024	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—TYK2—psoriasis	1.16e-05	0.000239	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.15e-05	0.000237	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—TYK2—psoriasis	1.14e-05	0.000235	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—CXCL8—psoriasis	1.14e-05	0.000235	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—CXCL8—psoriasis	1.12e-05	0.000231	CbGpPWpGaD
Haloperidol—DRD1—GPCR downstream signaling—CXCL8—psoriasis	1.11e-05	0.000229	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.1e-05	0.000226	CbGpPWpGaD
Haloperidol—DRD3—GPCR downstream signaling—CXCL8—psoriasis	1.09e-05	0.000226	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—APOE—psoriasis	1.09e-05	0.000225	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—CARM1—psoriasis	1.07e-05	0.000221	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—CXCL8—psoriasis	1.07e-05	0.00022	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.05e-05	0.000217	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—CARM1—psoriasis	1.05e-05	0.000216	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—APOE—psoriasis	1.03e-05	0.000213	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—LEP—psoriasis	1.03e-05	0.000213	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—LEP—psoriasis	1.01e-05	0.000208	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—APOE—psoriasis	1.01e-05	0.000208	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—CXCL8—psoriasis	1.01e-05	0.000208	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1e-05	0.000207	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—LEP—psoriasis	9.94e-06	0.000205	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—APOE—psoriasis	9.94e-06	0.000205	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—CXCL8—psoriasis	9.93e-06	0.000205	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—CARM1—psoriasis	9.86e-06	0.000204	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—CARM1—psoriasis	9.77e-06	0.000202	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—NFKBIA—psoriasis	9.61e-06	0.000198	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—PPARG—psoriasis	9.49e-06	0.000196	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—LEP—psoriasis	9.49e-06	0.000196	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—APOE—psoriasis	9.49e-06	0.000196	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—NFKBIA—psoriasis	9.41e-06	0.000194	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—NFKBIA—psoriasis	9.26e-06	0.000191	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—APOE—psoriasis	9.17e-06	0.000189	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—SOCS1—psoriasis	9.15e-06	0.000189	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.14e-06	0.000189	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—SOCS1—psoriasis	9.01e-06	0.000186	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—SOCS1—psoriasis	8.99e-06	0.000186	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.96e-06	0.000185	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—LEP—psoriasis	8.95e-06	0.000185	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—APOE—psoriasis	8.95e-06	0.000185	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—NFKBIA—psoriasis	8.84e-06	0.000182	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—LEP—psoriasis	8.83e-06	0.000182	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—APOE—psoriasis	8.83e-06	0.000182	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—TYK2—psoriasis	8.73e-06	0.00018	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—TYK2—psoriasis	8.59e-06	0.000177	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—TYK2—psoriasis	8.57e-06	0.000177	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—CAT—psoriasis	8.53e-06	0.000176	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—CXCL8—psoriasis	8.37e-06	0.000173	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CARM1—psoriasis	8.35e-06	0.000172	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—NFKBIA—psoriasis	8.34e-06	0.000172	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—CXCL8—psoriasis	8.23e-06	0.00017	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—NFKBIA—psoriasis	8.22e-06	0.00017	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—CXCL8—psoriasis	8.21e-06	0.00017	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—CAT—psoriasis	8.06e-06	0.000166	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—PPARG—psoriasis	7.98e-06	0.000165	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—TYK2—psoriasis	7.87e-06	0.000163	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.81e-06	0.000161	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—TYK2—psoriasis	7.71e-06	0.000159	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—CXCL8—psoriasis	7.6e-06	0.000157	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—TYK2—psoriasis	7.58e-06	0.000157	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—CXCL8—psoriasis	7.48e-06	0.000154	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—CXCL8—psoriasis	7.46e-06	0.000154	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—TYK2—psoriasis	7.24e-06	0.000149	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—CXCL8—psoriasis	6.85e-06	0.000141	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—TYK2—psoriasis	6.83e-06	0.000141	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—LEP—psoriasis	6.75e-06	0.000139	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—APOE—psoriasis	6.75e-06	0.000139	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—TYK2—psoriasis	6.74e-06	0.000139	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—CXCL8—psoriasis	6.71e-06	0.000139	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—LEP—psoriasis	6.65e-06	0.000137	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—APOE—psoriasis	6.65e-06	0.000137	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—APOE—psoriasis	6.63e-06	0.000137	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—LEP—psoriasis	6.63e-06	0.000137	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—APOE—psoriasis	6.63e-06	0.000137	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—CXCL8—psoriasis	6.6e-06	0.000136	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—CAT—psoriasis	6.59e-06	0.000136	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—IL6—psoriasis	6.52e-06	0.000135	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CARM1—psoriasis	6.45e-06	0.000133	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—CAT—psoriasis	6.43e-06	0.000133	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—IL6—psoriasis	6.38e-06	0.000132	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—JUN—psoriasis	6.37e-06	0.000132	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—CXCL8—psoriasis	6.3e-06	0.00013	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—NFKBIA—psoriasis	6.29e-06	0.00013	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—IL6—psoriasis	6.28e-06	0.00013	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—APOE—psoriasis	6.26e-06	0.000129	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—JUN—psoriasis	6.24e-06	0.000129	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—NFKBIA—psoriasis	6.19e-06	0.000128	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—NFKBIA—psoriasis	6.18e-06	0.000128	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—JUN—psoriasis	6.14e-06	0.000127	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—NFKB1—psoriasis	6.13e-06	0.000127	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—CAT—psoriasis	6.06e-06	0.000125	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—CAT—psoriasis	6.01e-06	0.000124	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—NFKB1—psoriasis	6.01e-06	0.000124	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—IL6—psoriasis	5.99e-06	0.000124	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CXCL8—psoriasis	5.94e-06	0.000123	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—NFKB1—psoriasis	5.91e-06	0.000122	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CXCL8—psoriasis	5.87e-06	0.000121	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—JUN—psoriasis	5.86e-06	0.000121	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PPARG—psoriasis	5.77e-06	0.000119	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—IL6—psoriasis	5.65e-06	0.000117	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—NFKB1—psoriasis	5.64e-06	0.000116	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—IL6—psoriasis	5.58e-06	0.000115	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—VEGFA—psoriasis	5.57e-06	0.000115	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—JUN—psoriasis	5.53e-06	0.000114	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—STAT3—psoriasis	5.51e-06	0.000114	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—JUN—psoriasis	5.45e-06	0.000113	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PPARG—psoriasis	5.45e-06	0.000113	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—VEGFA—psoriasis	5.45e-06	0.000113	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—STAT3—psoriasis	5.4e-06	0.000111	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—VEGFA—psoriasis	5.36e-06	0.000111	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—NFKB1—psoriasis	5.32e-06	0.00011	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—STAT3—psoriasis	5.31e-06	0.00011	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—NFKB1—psoriasis	5.25e-06	0.000108	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—TYK2—psoriasis	5.15e-06	0.000106	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CAT—psoriasis	5.14e-06	0.000106	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—APOE—psoriasis	5.12e-06	0.000106	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—VEGFA—psoriasis	5.12e-06	0.000106	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—TYK2—psoriasis	5.07e-06	0.000105	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—STAT3—psoriasis	5.07e-06	0.000105	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—TYK2—psoriasis	5.06e-06	0.000104	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—APOE—psoriasis	5e-06	0.000103	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—VEGFA—psoriasis	4.83e-06	9.97e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—STAT3—psoriasis	4.78e-06	9.87e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—VEGFA—psoriasis	4.76e-06	9.84e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—STAT3—psoriasis	4.72e-06	9.74e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—APOE—psoriasis	4.71e-06	9.73e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—APOE—psoriasis	4.67e-06	9.64e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CXCL8—psoriasis	4.49e-06	9.27e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PPARG—psoriasis	4.46e-06	9.21e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CXCL8—psoriasis	4.42e-06	9.12e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CXCL8—psoriasis	4.41e-06	9.1e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PPARG—psoriasis	4.36e-06	8.99e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—IL6—psoriasis	4.27e-06	8.81e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—TP53—psoriasis	4.21e-06	8.68e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—IL6—psoriasis	4.2e-06	8.67e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—IL6—psoriasis	4.19e-06	8.65e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—JUN—psoriasis	4.17e-06	8.61e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—TP53—psoriasis	4.12e-06	8.5e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—JUN—psoriasis	4.11e-06	8.48e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PPARG—psoriasis	4.1e-06	8.47e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—JUN—psoriasis	4.1e-06	8.46e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PPARG—psoriasis	4.07e-06	8.4e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—TP53—psoriasis	4.05e-06	8.37e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—NFKB1—psoriasis	4.02e-06	8.29e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—APOE—psoriasis	3.99e-06	8.24e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CAT—psoriasis	3.96e-06	8.19e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—NFKB1—psoriasis	3.95e-06	8.16e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—NFKB1—psoriasis	3.94e-06	8.14e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—TP53—psoriasis	3.87e-06	7.99e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—IL6—psoriasis	3.85e-06	7.95e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—IL6—psoriasis	3.77e-06	7.78e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—IL6—psoriasis	3.71e-06	7.66e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—TP53—psoriasis	3.65e-06	7.53e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—VEGFA—psoriasis	3.65e-06	7.53e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—STAT3—psoriasis	3.61e-06	7.45e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—TP53—psoriasis	3.6e-06	7.43e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—VEGFA—psoriasis	3.59e-06	7.41e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—VEGFA—psoriasis	3.58e-06	7.39e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—STAT3—psoriasis	3.55e-06	7.33e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—STAT3—psoriasis	3.54e-06	7.32e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—IL6—psoriasis	3.54e-06	7.31e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PPARG—psoriasis	3.48e-06	7.18e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—IL6—psoriasis	3.34e-06	6.89e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—IL6—psoriasis	3.29e-06	6.8e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—APOE—psoriasis	3.08e-06	6.36e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—TP53—psoriasis	2.75e-06	5.69e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—TP53—psoriasis	2.71e-06	5.6e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—TP53—psoriasis	2.7e-06	5.58e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PPARG—psoriasis	2.68e-06	5.54e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—IL6—psoriasis	2.52e-06	5.21e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—IL6—psoriasis	2.48e-06	5.12e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—IL6—psoriasis	2.48e-06	5.11e-05	CbGpPWpGaD
